Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

XOLINE TABLET 500MCG [SIN17275P]

Active ingredients: XOLINE TABLET 500MCG

View product's general information
Last updated 24 April 2026

Product Info

XOLINE TABLET 500MCG

[SIN17275P]

Product information

Active Ingredient and Strength

COLCHICINE - 0.5 MG

Dosage Form

TABLET

Manufacturer and Country

RENATA PLC - BANGLADESH

Registration Number

SIN17275P

Licence Holder

SEA PHARMA CONSULTANCY PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

M04AC01

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications
Adults
Treatment of acute gout.

Dosing

4.2 Posology and method of administration
Posology
Adults
Treatment of acute gout attack:
1 mg (2 tablets of 500 micrograms) to be taken initially followed by 500 micrograms every two to three hours until pain subsides. A total dose of 6 mg should not be exceeded. After completion of a course, another course should not be started for at least three days.

Patients with renal impairment
Use with caution in patients with mild renal impairment. For patients with moderate renal impairment, reduce dose or increase interval between doses. Such patients should be carefully monitored for adverse effects of colchicine (see also section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
For patients with severe renal impairment, see section 4.3.

Patients with hepatic impairment
Use with caution in patients with mild/moderate hepatic impairment. Such patients should be carefully monitored for adverse effects of colchicine.
For patients with severe hepatic impairment, see section 4.3.

Elderly
Use with caution.

Method of administration
For oral administration
Tablets should be swallowed whole with a glass of water.

Contraindications

4.3 Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

  • Patients with blood dyscrasias

  • Pregnancy

  • Breastfeeding

  • Women of childbearing potential unless using effective contraceptive measures

  • Patients with severe renal impairment

  • Patients with severe hepatic impairment

  • Colchicine should not be used in patients undergoing haemodialysis since it cannot be removed by dialysis or exchange transfusion.

  • Colchicine is contraindicated in patients with renal or hepatic impairment who are taking a P-glycoprotein (P-gp) inhibitor or a strong CYP3A4 inhibitor (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)